THE ROLE OF BEHAVIORAL AND METABOLIC FACTORS IN THE DEVELOPMENT OF ADAPTIVE DISORDERS IN WOMEN DURING MENOPAUSE
DOI:
https://doi.org/10.55640/Keywords:
menopause, adaptive disorders, metabolic remodeling, lifestyle factors, insulin resistance, visceral adiposity, circadian dysregulationAbstract
Menopause is a biologically determined stage of female aging accompanied by profound endocrine, metabolic, and neuroregulatory transformations. Although it represents a physiological transition, menopause is frequently associated with the development of adaptive disorders that compromise metabolic stability, psychoemotional balance, and cardiovascular health. Considerable interindividual variability in clinical manifestations suggests a decisive influence of modifiable behavioral and metabolic determinants.
This narrative review analyzes current scientific evidence regarding the mechanisms through which metabolic alterations and lifestyle-related factors contribute to maladaptive responses during the menopausal transition and early postmenopause. Particular emphasis is placed on estrogen deficiency–mediated metabolic remodeling, visceral adipose tissue accumulation, insulin resistance, circadian rhythm disruption, chronic low-grade inflammation, and behavioral patterns affecting energy homeostasis.
Available data indicate that menopause constitutes a critical period of increased metabolic sensitivity, during which unfavorable lifestyle factors may accelerate biological aging and disease progression. Conversely, timely behavioral modification and metabolic correction appear capable of significantly improving adaptive capacity and long-term health outcomes.
Downloads
References
1.Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., … Smith, S. C. (2009). Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention. Circulation, 120(16), 1640–1645. https://doi.org/10.1161/CIRCULATIONAHA.109.192644
2.Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S. E., Legro, R. S., & Yildiz, B. O. (2016). Polycystic ovary syndrome. Nature Reviews Disease Primers, 2, 16057. https://doi.org/10.1038/nrdp.2016.57
3.Barber, T. M., Hanson, P., Weickert, M. O., & Franks, S. (2019). Obesity and polycystic ovary syndrome: Implications for pathogenesis and novel management strategies. Clinical Medicine Insights: Reproductive Health, 13, 1–9. https://doi.org/10.1177/1179558119874042
4.Bednarska, S., & Siejka, A. (2017). The pathogenesis and treatment of polycystic ovary syndrome: What’s new? Advances in Clinical and Experimental Medicine, 26(2), 359–367. https://doi.org/10.17219/acem/59380
5.Bucci, D., Muscogiuri, G., Colao, A., & Savastano, S. (2020). Obesity, metabolic syndrome and infertility: A new therapeutic approach. Journal of Endocrinological Investigation, 43(7), 843–852. https://doi.org/10.1007/s40618-020-01214-8
6.Carter, S., & Davies, M. (2012). Metabolic syndrome and reproductive health. Best Practice & Research Clinical Obstetrics & Gynaecology, 26(1), 1–12. https://doi.org/10.1016/j.bpobgyn.2011.08.004
7.Diamanti-Kandarakis, E., Dunaif, A., & Katsikis, I. (2020). Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. Endocrine Reviews, 41(2), 1–32. https://doi.org/10.1210/endrev/bnaa001
8.Duleba, A. J., & Dokras, A. (2012). Is PCOS an inflammatory process? Fertility and Sterility, 97(1), 7–12. https://doi.org/10.1016/j.fertnstert.2011.11.023
9.Escobar-Morreale, H. F. (2018). Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment. Nature Reviews Endocrinology, 14(5), 270–284. https://doi.org/10.1038/nrendo.2018.24
10.Fenkci, S. M., Fenkci, V., Yilmazer, M., & Serteser, M. (2003). Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome. Gynecological Endocrinology, 17(4), 283–288. https://doi.org/10.1080/0951359031000111871
11.Gambineri, A., Pelusi, C., Vicennati, V., Pagotto, U., & Pasquali, R. (2002). Obesity and the polycystic ovary syndrome. International Journal of Obesity, 26(7), 883–896. https://doi.org/10.1038/sj.ijo.0801994
12.González, F. (2012). Inflammation in polycystic ovary syndrome: Underpinning of insulin resistance and ovarian dysfunction. Steroids, 77(4), 300–305. https://doi.org/10.1016/j.steroids.2011.12.003
13.Grundy, S. M. (2016). Metabolic syndrome update. Trends in Cardiovascular Medicine, 26(4), 364–373. https://doi.org/10.1016/j.tcm.2015.10.004
14.Ibrahim, M. A., & Abdel-Gadir, A. (2020). Ovarian morphology and metabolic syndrome: Pathophysiological correlations. Reproductive Biology and Endocrinology, 18, 1–10. https://doi.org/10.1186/s12958-020-00645-1
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
